Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
November 22 2023 - 7:00AM
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage
biopharmaceutical company developing novel fatty acid synthase
(FASN) inhibitors that target dysfunctional metabolic pathways,
today announced its participation in the upcoming 35th Annual Piper
Sandler Healthcare Conference being held in New York. David Happel,
Chief Executive Officer, and Eduardo Bruno Martins, M.D., D.Phil.,
Chief Medical Officer, are scheduled to participate in a fireside
chat at 3:30 p.m. ET / 12:30 p.m. PT on Wednesday, November 29,
2023, and will also hold one-on-one meetings with investors.
A webcast of the fireside chat will be available in the
Investors & Media Section of Sagimet’s website at
www.sagimet.com, with an archived replay available following the
live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing
novel fatty acid synthase (FASN) inhibitors that target
dysfunctional metabolic pathways in diseases resulting from the
overproduction of the fatty acid, palmitate. Sagimet’s lead drug
candidate, denifanstat, is an oral, once-daily pill and selective
FASN inhibitor in development for the treatment of NASH, for which
there are no treatments currently approved in the United States or
Europe. Denifanstat is currently being tested in FASCINATE-2, a
Phase 2b clinical trial in NASH with liver biopsy as the primary
endpoint. For additional information about Sagimet, please visit
www.sagimet.com.
Contact:
Maria YonkoskiICR
Westwicke203-682-7167maria.yonkoski@westwicke.com
Sagiment Biosciences (NASDAQ:SGMT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sagiment Biosciences (NASDAQ:SGMT)
Historical Stock Chart
From Sep 2023 to Sep 2024